FDMT Insider Glenn Sblendorio Buys 50,000 Shares
Glenn Sblendorio purchased 50,000 shares of 4D Molecular Therapeutics, Inc. on June 17, 2026, amid a surge of insider buying.
Reviewed by automated data checks against the source filing. How we make and check alerts
Glenn Sblendorio bought 50,000 shares of 4D Molecular Therapeutics, Inc. ($FDMT) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $FDMT is up 23.4% after 1 week, up 16.7% after 1 month and up 28.9% to date (from the $9.42 close on Jun 17, 2026).
FDMT
4D Molecular Therapeutics, Inc.
Key Points
- On June 17, Glenn Sblendorio bought 50,000 shares of 4D Molecular Therapeutics (FDMT) at a price of $9.66 each.
- Other insiders also purchased significant shares on the same day, including John Milligan, who bought 75,000 shares.
- Analysts maintain a strong buy consensus on 4D Molecular Therapeutics, with a mean price target of $27.82.
Get $FDMT trade alerts by text
We text you when insiders, Congress or big funds trade $FDMT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated 4D Molecular Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at 4D Molecular Therapeutics, Inc.
On June 17, 2026, Glenn Sblendorio bought 50,000 shares of 4D Molecular Therapeutics, Inc. (FDMT) at a price of $9.66 each. This purchase comes amid a notable wave of insider buying at the company, which has seen other executives make similar purchases on the same day.
Other Insiders Join the Buying
Sblendorio's purchase is part of a broader trend at 4D Molecular Therapeutics. On the same date, several other insiders also acquired shares. Shawn Tomasello, Nancy Miller-Rich, Jacob Chacko, and Susannah Gray each bought 50,000 shares, while John Milligan made a larger purchase of 75,000 shares. This collective buying activity suggests a strong belief in the company's direction.
How 4D Molecular Therapeutics, Inc. Stock Has Traded
As of June 17, 2026, shares of 4D Molecular Therapeutics traded at $9.66. This price is significantly below its 52-week high of $16.93, indicating potential upside for investors. The stock has seen considerable fluctuations, with a 52-week low of $6.96, making current levels an interesting point for those looking at the stock.
Analysts Set New Price Targets
Analysts maintain a strong buy consensus for 4D Molecular Therapeutics. On October 6, 2026, Chardan Capital maintained a Buy rating with a target price of $25. B of A Securities also kept a Buy rating but raised its target from $29 to $33 on September 29, 2026. Additionally, Cantor Fitzgerald upgraded the stock to Overweight on September 14, 2026, with a target of $20. The general sentiment among analysts points to optimism about the company's future prospects.
What 4D Molecular Therapeutics, Inc. Does
4D Molecular Therapeutics is a late-stage biotechnology firm focused on developing adeno-associated virus vectors for gene therapies. Its lead product candidate aims to treat retinal vascular diseases, showcasing the company's innovative approach to healthcare solutions. The recent insider buying could reflect confidence in the upcoming developments and potential market performance.
What's Ahead for 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics is expected to report its next earnings on November 10, 2026. As the company continues to attract insider interest, it will be crucial to monitor how these trades influence market sentiment and performance leading up to the earnings report. Remember, the recent insider transactions reflect past positions and may not indicate current holdings.
Related Filing Alerts
Source: Glenn Sblendorio's Form 4 filing on $FDMT (Jun 17, 2026). Find the original filing: FDMT Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts